BeiGene
ONC
#700
Rank
โ‚น2.405 T
Marketcap
โ‚น21,197
Share price
-3.14%
Change (1 day)
76.48%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : โ‚น221.15 Billion

According to BeiGene 's latest financial reports the company's total liabilities are โ‚น221.15 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚น222.07 B17.62%
2023-12-31โ‚น188.80 B14.31%
2022-12-31โ‚น165.16 B-7.66%
2021-12-31โ‚น178.85 B41.24%
2020-12-31โ‚น126.63 B180.12%
2019-12-31โ‚น45.20 B30.34%
2018-12-31โ‚น34.68 B49.95%
2017-12-31โ‚น23.12 B543.35%
2016-12-31โ‚น3.59 B27.46%
2015-12-31โ‚น2.82 B59.79%
2014-12-31โ‚น1.76 B-43.45%
2013-12-31โ‚น3.12 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚น1.03 B-99.53%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น71.31 B-67.75%๐Ÿ‡บ๐Ÿ‡ธ USA